DEF: PURE Bioscience Seeks Share Increase Amid Financial Constraints

PURE Bioscience, Inc. will hold its 2026 Annual Meeting to vote on director elections, auditor ratification, executive compensation, and a proposal to increase authorized common stock from 200 million to 250 million shares.

Summary

• The Annual Meeting of Stockholders is scheduled for February 17, 2026, at 10:30 a.m. local time in Huntington Beach, CA.
• Stockholders will vote on four key proposals: election of seven directors, ratification of Weinberg & Company, P.A. as independent auditors for FY2026, a non-binding advisory vote on FY2025 executive compensation, and an amendment to increase authorized common stock from 200,000,000 to 250,000,000 shares.
• The Board of Directors unanimously recommends a vote FOR all proposals.
• As of December 22, 2025, 111,886,485 shares of Common Stock were issued and outstanding.
• The company has financed operations primarily through public and private offerings of securities, debt financing, and revenue from product sales and license agreements, and anticipates needing additional capital for product development and business plan implementation.
• Executive and director cash compensation was voluntarily reduced in FY2025 and further reduced or eliminated subsequent to July 31, 2025, due to limited financial resources and performance below the operating plan.
• Named executive officers did not receive cash bonuses for FY2025 and FY2024.

Sentiment

Score: 3

Explanation: The filing reveals significant financial challenges, including voluntary executive and director salary reductions, absence of executive bonuses, and consistent net losses. The primary purpose of increasing authorized shares is to facilitate future capital raises, indicating a reliance on external funding to sustain operations and growth. While corporate governance appears sound, the underlying financial performance is a major concern.

Positives

• The company maintains high standards of business conduct and corporate governance, with established Corporate Governance Guidelines and a Code of Business Conduct and Ethics.
• The Board of Directors includes four independent members (Messrs. Chen, Rendall, Blotner, and Zehr) out of seven, adhering to NYSE American listing standards.
• The Audit Committee is comprised solely of independent directors, with Messrs. Chen, Blotner, and Rendall identified as audit committee financial experts.
• The roles of Chairman of the Board (Mr. Chen) and Chief Executive Officer (Mr. Bartlett) are separated, which the Board believes enhances accountability and balanced decision-making.
• The Board is actively involved in risk oversight, with specific committees addressing relevant risk areas.
• Stockholders approved the "Say on Pay" proposal at the 2025 Annual Meeting with 95.49% of votes cast.

Negatives

• Named executive officers did not receive any performance-based cash bonuses for the fiscal years ended July 31, 2025, and 2024, due to limited financial resources and performance below the operating plan.
• Executive salaries were voluntarily reduced during FY2025: Robert Bartlett from $200,000 to $100,000; Mark Elliott from $180,000 to $157,500; Tom Myers from $200,000 to $175,000.
• Subsequent to July 31, 2025, executive salaries were further voluntarily reduced: Robert Bartlett to $80,000; Mark Elliott to $147,500; Tom Myers to $155,000.
• Board cash compensation for non-employee directors was voluntarily reduced by half during Q3 FY2025 and subsequently eliminated after July 31, 2025.
• The company reported net losses of $2,400,000 in FY2025, $3,350,000 in FY2024, and $3,961,000 in FY2023.
• The company explicitly states it needs additional capital to fund product development and implement its business plan, and will need to continue funding operations with proceeds from equity and debt securities until positive cash flow is consistently generated.

Risks

• Potential inability to access capital markets and raise necessary capital to execute the business plan.
• Risk of not being able to attract, retain, and motivate employees if compensation is constrained due to financial limitations.
• Inability to pursue other business opportunities integral to growth and success if capital is insufficient.
• Dilution of earnings per share and voting rights for current stockholders if the authorized number of shares is increased and new shares are issued.
• Uncertainty that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the company or its stockholders.
• The increase in authorized common stock could make it more difficult or discourage attempts to obtain control of the Company, implicitly acting as an anti-takeover effect, though the Board does not view it as such.

Future Outlook

The company anticipates needing additional capital to fund product development and implement its business plan, intending to cover future operating expenses through cash on hand, product sales revenue, and the issuance of additional equity or debt securities. The proposed increase in authorized common stock is designed to enhance flexibility for future capital raises, stock-based acquisitions, and equity compensation awards without requiring further stockholder approval at the time of need.

Management Comments

• "We are pleased to take advantage of the rules established by the Securities and Exchange Commission (the SEC) that allow companies to furnish proxy materials primarily over the internet. We believe that this will allow us to promptly provide proxy materials to you, while lowering the costs of distribution and reducing the environmental impact of our annual meeting." (Robert Bartlett, CEO)
• "Whether or not you plan to attend the meeting, your vote is very important and we encourage you to vote promptly." (Robert Bartlett, CEO)
• "Our Board believes our leadership structure enhances the accountability of our Chief Executive Officer to the Board and encourages balanced decision making."
• "The Board and Compensation Committee believe the Company’s executive compensation program uses appropriate structures and sound pay practices that are effective in achieving the Company’s core compensation objectives."
• "If our stockholders do not approve the Charter Amendment, we may not be able to access the capital markets and raise the capital necessary to execute on our business plan; attract, retain and motivate our employees; or pursue other business opportunities integral to our growth and success."

Industry Context

The company operates in an industry where product development and business plan implementation often require significant capital investment. The reliance on equity and debt financings, coupled with voluntary compensation reductions, suggests a challenging financial environment, potentially reflecting broader pressures or specific company-level hurdles in securing consistent positive cash flow from operations. The need to increase authorized shares for future capital raises is a common strategy for growth-oriented companies, but the context of ongoing net losses and compensation cuts indicates a more urgent need for funding.

Comparison to Industry Standards

• The voluntary reduction of executive and director cash compensation, and the absence of executive cash bonuses for two consecutive years, are not typical for financially healthy companies and suggest performance below industry benchmarks or significant financial constraints.
• The consistent net losses over the past three fiscal years ($2.4M, $3.35M, $3.961M) indicate that the company is not yet achieving profitability, which contrasts with established, profitable industry players.
• The reliance on convertible debt financings ($1.015M in FY2023, $1.785M in FY2024, $2.0M in FY2025) and the explicit need for future equity or debt capital to fund operations and development suggest a capital-intensive business model or insufficient internal cash generation compared to industry peers with stable operations.
• The proposal to increase authorized shares to facilitate future capital raises is a common practice, but the urgency and the stated risk of not being able to execute the business plan without it, imply a more critical financial position than typically seen in well-capitalized industry leaders.

Management Changes

Corporate Governance

Related Party Transactions

• Tom Y. Lee, a director, invested $500,000 in the 2025 Private Placement (2025 Note Purchase Agreement) on September 16, 2024, and an additional $1,500,000 during FY2025 through affiliates or directly.
• Tom Y. Lee invested $500,000 in the 2024 Private Placement (2024 Note Purchase Agreement) on March 22, 2024, and an additional $500,000 on June 21, 2024.
• Tom Y. Lee invested $1,000,000 and Ivan Chen, a director, invested $15,000 in the 2023 Private Placement (2023 Note Purchase Agreement) in July 2023. An additional $785,000 was issued to Mr. Lee on October 20, 2023.
• The disinterested members of the Board approved these private placements.
• Ivan Chen is the nephew of Tom Y. Lee.

Stakeholder Impact

• Shareholders: Potential dilution of earnings per share and voting rights if the proposed increase in authorized common stock is approved and new shares are issued for capital raising or other corporate purposes.
• Employees/Executives: Voluntary salary reductions and absence of cash bonuses indicate financial strain, potentially impacting morale and retention, though long-term equity awards are used as an incentive.
• Creditors: The company's reliance on convertible debt financings and ongoing need for capital raises may be a factor for creditors assessing risk.
• Customers/Suppliers: The need for capital to fund product development and business plan implementation suggests potential for future growth and product offerings, but also implies current operational limitations.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on February 17, 2026, to vote on the proposals.
• If the Charter Amendment is approved, the company intends to promptly file the Certificate of Amendment with the Secretary of State of Delaware.
• The Audit Committee will reconsider its selection of auditors if stockholders fail to ratify the appointment of Weinberg & Company, P.A.
• The Compensation Committee and Board will review the voting results of the Say on Pay proposal and take them into consideration for future executive compensation decisions.
• The Board intends to carefully evaluate from time to time whether the Chief Executive Officer and Chairman positions should remain separate.
• The company will report final voting results in a Form 8-K report filed with the SEC.
• Stockholders interested in submitting proposals for the 2027 Annual Meeting must do so by September 1, 2026 (for inclusion in proxy materials) or provide advance notice according to bylaws.

Key Dates

Recommendation

The filing highlights significant financial challenges, including voluntary executive and director salary reductions, a lack of executive cash bonuses for two consecutive years, and consistent net losses. The proposal to increase authorized common stock is explicitly aimed at facilitating future capital raises, which, while necessary for funding product development and the business plan, signals ongoing reliance on external financing and potential dilution for existing shareholders. While the company demonstrates sound corporate governance and a clear strategy for future funding, the current financial performance and the need for substantial external capital warrant a cautious 'hold' stance. Investors should monitor the success of future capital raises and progress towards achieving positive cash flow from operations before considering a more aggressive position.

Keywords

PURE Bioscience, Proxy Statement, Annual Meeting, Stockholder Vote, Corporate Governance, Executive Compensation, Authorized Shares, Capital Raise, SEC Filing, Financial Performance, Director Election, Auditor Ratification, Dilution, Convertible Debt